2.85
price down icon4.36%   -0.13
 
loading
Exagen Inc stock is traded at $2.85, with a volume of 34,810. It is down -4.36% in the last 24 hours and down -1.04% over the past month. Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
See More
Previous Close:
$2.98
Open:
$3.06
24h Volume:
34,810
Relative Volume:
1.16
Market Cap:
$50.68M
Revenue:
$52.55M
Net Income/Loss:
$-23.69M
P/E Ratio:
-1.4109
EPS:
-2.02
Net Cash Flow:
$-15.29M
1W Performance:
-4.04%
1M Performance:
-1.04%
6M Performance:
+51.60%
1Y Performance:
+81.32%
1-Day Range:
Value
$2.78
$3.08
1-Week Range:
Value
$2.62
$3.084
52-Week Range:
Value
$1.3003
$3.71

Exagen Inc Stock (XGN) Company Profile

Name
Name
Exagen Inc
Name
Phone
(760) 560-1501
Name
Address
1261 LIBERTY WAY, VISTA, CA
Name
Employee
179
Name
Twitter
@ExagenInc
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
XGN's Discussions on Twitter

Compare XGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
XGN 2.87 50.68M 52.55M -23.69M -15.29M -2.02
TMO 500.25 192.46B 42.37B 6.14B 7.78B 15.26
DHR 229.65 165.90B 23.74B 3.89B 4.98B 7.93
A 126.30 36.48B 6.50B 1.41B 1.42B 3.82
IDXX 421.38 34.55B 3.84B 866.24M 792.60M 9.80
IQV 190.39 34.31B 15.32B 1.41B 1.96B 5.95

Exagen Inc Stock (XGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-05-22 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Oct-15-21 Resumed Cowen Outperform
Apr-15-21 Initiated Canaccord Genuity Buy
Nov-10-20 Initiated KeyBanc Capital Markets Overweight
Oct-08-20 Initiated BTIG Research Buy
Jun-02-20 Resumed Cantor Fitzgerald Overweight
Oct-14-19 Initiated Cantor Fitzgerald Overweight
Oct-14-19 Initiated Cowen Outperform
Oct-14-19 Initiated William Blair Outperform
View All

Exagen Inc Stock (XGN) Latest News

pulisher
01:56 AM

What is William Blair's Forecast for Exagen FY2024 Earnings? - MarketBeat

01:56 AM
pulisher
01:56 AM

Cantor Fitzgerald Raises Earnings Estimates for Exagen - MarketBeat

01:56 AM
pulisher
01:20 AM

Cantor Fitzgerald Increases Earnings Estimates for Exagen - Defense World

01:20 AM
pulisher
Nov 15, 2024

Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 15, 2024
pulisher
Nov 15, 2024

William Blair Reiterates “Outperform” Rating for Exagen (NASDAQ:XGN) - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Exagen unveils new biomarkers to enhance autoimmune testing - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Exagen Inc. Completes Validation and Regulatory Submission - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Exagen Enhances AVISE CTD Platform with 7 New Biomarkers for Autoimmune Disease Detection | XGN Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Exagen Inc. to Participate in Fourth Quarter Investor Conferences - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Exagen stock holds Sector Weight amid mixed 3Q24 results By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

Exagen CEO to Present at Three Major Healthcare Investor Conferences | XGN Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Exagen (NASDAQ:XGN) Receives Outperform Rating from William Blair - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Exagen Inc. (NASDAQ:XGN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024
pulisher
Nov 13, 2024

Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Ch - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... - Yahoo Finance

Nov 13, 2024
pulisher
Nov 12, 2024

Exagen Inc. Reports Q3 2024 Financial Results - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Exagen Inc. (XGN) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 12, 2024

Exagen stock holds Sector Weight amid mixed 3Q24 results - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

Exagen Inc (XGN) Q3 2024 Earnings: Revenue Misses Estimates at $12.5M, Net Loss Narrows to $5.0M - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Exagen Inc. Reports Third Quarter 2024 Results - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Exagen Q3 Revenue Hits $12.5M Despite Setbacks; YTD Performance Shows 37% Loss Reduction | XGN Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect - GuruFocus.com

Nov 11, 2024
pulisher
Nov 10, 2024

Exagen (XGN) to Release Earnings on Tuesday - Defense World

Nov 10, 2024
pulisher
Oct 29, 2024

Exagen to Announce Third Quarter 2024 Results on November 12, 2024 - GlobeNewswire

Oct 29, 2024
pulisher
Oct 22, 2024

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence - The Manila Times

Oct 22, 2024
pulisher
Oct 14, 2024

Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World

Oct 14, 2024
pulisher
Oct 12, 2024

Exagen Insider Stock Sales Prove Timely As Market Valuation Descends To US$47m - Simply Wall St

Oct 12, 2024
pulisher
Oct 01, 2024

Stonepine Capital Management LLC Has $653,000 Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Exagen Inc. (NASDAQ:XGN) Shares Sold by Nantahala Capital Management LLC - Defense World

Oct 01, 2024
pulisher
Sep 30, 2024

Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges - Investing.com

Sep 30, 2024
pulisher
Sep 28, 2024

Exagen Inc. (NASDAQ:XGN) Short Interest Up 20.9% in September - MarketBeat

Sep 28, 2024
pulisher
Sep 25, 2024

Octopus Energy acquires solar and storage company Exagen Group - Yahoo Finance

Sep 25, 2024
pulisher
Sep 24, 2024

Octopus buys British solar and battery storage firm Exagen - Reuters

Sep 24, 2024
pulisher
Sep 23, 2024

PARP Inhibitor Biomarkers Market Expected to Reach $1.75 Billion by 2031 - WhaTech

Sep 23, 2024
pulisher
Sep 20, 2024

Autoimmune Disease Diagnostics Market 2024 Global Insights and Business Scenario 2031 - Newstrail

Sep 20, 2024
pulisher
Sep 18, 2024

San Diego 2024 Top Tech Awards ceremony set for Sept. 26 at Snapdragon Stadium - CBS News 8

Sep 18, 2024
pulisher
Sep 18, 2024

Autoimmune Disease Testing Market to Reach $12.1 Billion, Globally, by 2033 at 8.6% CAGR: Allied Market Research - PR Newswire UK

Sep 18, 2024
pulisher
Sep 13, 2024

Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now - MSN

Sep 13, 2024
pulisher
Sep 13, 2024

Shareholders in Exagen (NASDAQ:XGN) have lost 84%, as stock drops 12% this past week - Yahoo Finance

Sep 13, 2024
pulisher
Sep 10, 2024

PARP Inhibitor Biomarkers Market to Surge with 8.8% CAGR by 2031 - WhaTech

Sep 10, 2024
pulisher
Sep 06, 2024

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified - Simply Wall St

Sep 06, 2024
pulisher
Sep 04, 2024

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference - ForexTV.com

Sep 04, 2024
pulisher
Aug 28, 2024

Exagen Inc. (NASDAQ:XGN) Short Interest Down 41.5% in August - MarketBeat

Aug 28, 2024
pulisher
Aug 28, 2024

Short Interest in Exagen Inc. (NASDAQ:XGN) Decreases By 41.5% - Defense World

Aug 28, 2024
pulisher
Aug 26, 2024

Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock - Yahoo Finance

Aug 26, 2024
pulisher
Aug 23, 2024

Matthew G. Brown - Wilson Sonsini

Aug 23, 2024
pulisher
Aug 23, 2024

Detailed Analysis of Personalized Medicine Market Exploring Future Growth Potential, New Developments, Comp... - WhaTech

Aug 23, 2024
pulisher
Aug 19, 2024

XGN (Exagen) EBITDA : $-13.05 Mil (TTM As of Jun. 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 19, 2024

XGN (Exagen) Debt-to-EBITDA : -3.02 (As of Jun. 2024) - GuruFocus.com

Aug 19, 2024

Exagen Inc Stock (XGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$150.19
price up icon 2.78%
diagnostics_research LH
$238.78
price up icon 1.53%
diagnostics_research WAT
$353.45
price down icon 1.40%
$133.66
price down icon 1.05%
diagnostics_research MTD
$1,175.40
price down icon 0.49%
diagnostics_research IQV
$190.79
price down icon 1.07%
Cap:     |  Volume (24h):